Skip to main content

Clinical Trials Using Doxorubicin Hydrochloride

Review the clinical trials studying doxorubicin hydrochloride on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 29

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 375 locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 199 locations
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients with Newly Diagnosed Osteosarcoma
Status: Active
Location: 163 locations
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Status: Active
Location: 146 locations
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Status: Active
Location: 206 locations
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Status: Active
Location: 199 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 35 locations
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Status: Active
Location: 10 locations
Mogamulizumab with DA-EPOCH for the Treatment of Aggressive T-cell Non-Hodgkin Lymphoma
Status: Active
Location: 9 locations
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Status: Active
Location: 8 locations
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with CD30-Positive Peripheral T-cell Lymphoma
Status: Active
Location: 5 locations
Glofitamab plus Polatuzumab-R-CHP for the Treatment of High-Risk Diffuse Large B-Cell Lymphoma
Status: Active
Location: 4 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 3 locations
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status: Active
Location: 3 locations
Ruxolitinib in Combination with Standard Chemotherapy in Treating Adolescents and Young Adults with Ph-Like Acute Lymphoblastic Leukemia
Status: Active
Location: 3 locations
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Status: Active
Location: 2 locations
A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Status: Active
Location: 4 locations
Doxorubicin for the Treatment of Elderly Patients with Advanced or Metastatic Soft Tissue Leiomyosarcoma
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 150 locations